文献速递妇科

卡贝缩宫素减少腹腔镜子宫肌瘤剔除术出血的随机对照试验

Evaluating efficacy of intravenous carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial.
PubMed 文献 · Fertil Steril · 2021-01-16

这项随机双盲安慰剂对照试验纳入138例子宫症状性肌瘤拟行开腹子宫肌瘤剔除术的患者,1:1分为卡贝缩宫素组与安慰剂组,麻醉诱导后缓慢静脉给予100 μg卡贝缩宫素或安慰剂。结果显示卡贝缩宫素组术中出血量显著更少(平均差184 mL),术后24小时血红蛋白更高,输血人数更少,手术时间、住院时长与副作用两组相似。

要点

  • 麻醉诱导后单次静脉100 μg卡贝缩宫素可显著减少开腹子宫肌瘤剔除术术中出血。
  • 卡贝缩宫素组术后24小时血红蛋白高于安慰剂组,输血需求更少。
  • 手术时间、住院时长及药物副作用两组无显著差异。

核心结论

  • 单次术前静脉100 μg卡贝缩宫素是减少开腹子宫肌瘤剔除术术中出血及输血需求的简单、实用且有效的方法,副作用可耐受、少且无显著差异。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,2019年9月至2020年2月在一家三级大学医院开展;共纳入138例有症状的子宫肌瘤拟行开腹子宫肌瘤剔除术患者,每组69例,按1:1随机分组。

主要发现

  • 卡贝缩宫素组术中出血量显著低于安慰剂组,平均差184 mL。
  • 术后24小时血红蛋白安慰剂组显著低于卡贝缩宫素组(9.1 ± 0.8 vs. 10.3 ± 0.6 g/dL)。
  • 卡贝缩宫素组8例需要输血,安慰剂组17例。
  • 手术时间、住院时长及副作用两组相似。

关键数值与推荐

  • 干预为麻醉诱导后缓慢静脉给予100 μg卡贝缩宫素或安慰剂。
  • 主要结局包括术中出血量、输血需求、术后血红蛋白、手术时间、住院时长及药物副作用。

临床怎么用

  • 对拟行开腹子宫肌瘤剔除术的患者,可考虑术前单次静脉100 μg卡贝缩宫素以减少术中出血和输血。
  • 用药后仍需常规监测血红蛋白与输血需求,副作用总体可耐受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of carbetocin versus placebo in decreasing intraoperative blood loss and the need for blood transfusion during abdominal myomectomy. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Tertiary university hospital from September 2019 to February 2020. PATIENT(S): A total of 138 women with symptomatic leiomyoma who were candidates for abdominal myomectomy (n = 69 in each group). INTERVENTION(S): We randomized the study participants in a 1:1 ratio to carbetocin and placebo groups. Intravenous 100 μg carbetocin or placebo was administered slowly after induction of anesthesia. MAIN OUTCOME MEASURE(S): Intraoperative blood loss, need for blood transfusion, postoperative hemoglobin, operative time, length of hospitalization, and drug side-effects. RESULT(S): The baseline characteristics were similar among all groups. Carbetocin had significantly lower intraoperative blood loss compared with placebo (mean difference 184 mL). Hemoglobin level 24 hours after surgery was significantly lower in the placebo group than in the carbetocin group (9.1 ± 0.8 vs. 10.3 ± 0.6 g/dL). Eight women in the carbetocin group needed blood transfusion compared with 17 in placebo group. Operative time, length of hospitalization, and side-effects were similar in both groups. CONCLUSION(S): A single preoperative intravenous dose of 100 μg carbetocin is a simple, practical, and effective method of decreasing intraoperative blood loss and the need for blood transfusion during abdominal myomectomy, with tolerable, few, nonsignificant side-effects. CLINICAL TRIAL REGISTRATION NUMBER: NCT04083625.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Taher A, Farouk D, Mohamed Kotb MM, et al. Evaluating efficacy of intravenous carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial. Fertil Steril. 2021. PMID: 33461754. doi:10.1016/j.fertnstert.2020.09.132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。